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Chapter 7
The Effect of Vitamin D Supplementation on its Metabolism 
and the Vitamin D Metabolite Ratio
Francic V, Ursem SR, Dirks NF, Keppel MH, Theiler-Schwetz V, Trummer C, Pandis 
M, Borzan V, Grübler MR, Verheyen ND, März W, Tomaschitz A, Pilz A, Heijboer 
AC, Obermayer-Pietsch B 




Background: 25-hydroxyvitamin D (25(OH)D) is commonly measured to assess 
vitamin D status. Other vitamin D metabolites such as 24,25-dihydroxyvitamin D 
(24,25(OH)2D) provide additional insights into vitamin D status or metabolism. 
Earlier studies suggested that the vitamin D metabolite ratio (VMR), calculated 
as 24,25(OH)2D/25(OH)D, could predict the 25(OH)D increase after vitamin D 
supplementation. However, the evidence for this additional value is inconclusive. 
Therefore, our aim was to assess whether the increase in 25(OH)D after 
supplementation was predicted by VMR better than baseline 25(OH)D. 
Methods: Plasma samples of 106 vitamin D insufficient (25(OH)D < 75 nmol/L) 
individuals with hypertension who completed the Styrian Vitamin D Hypertension 
Trial (NCT02136771) were analyzed. Participants received vitamin D (2800IE 
daily) or placebo for 8 weeks. 
Results: The treatment effect (ANCOVA) for 25(OH)D3, 24,25(OH)2D3 and 
VMR was 32 nmol/L, 3.3 nmol/L and 0.015 (all p< 0.001), respectively. Baseline 
25(OH)D3 and 24,25(OH)2D3 predicted the change in 25(OH)D3 with comparable 
strength and magnitude. Correlation and regression analysis showed that VMR did 
not predict the change in 25(OH)D3. 
Conclusions: Therefore, our data do not support routine measurement 
of 24,25(OH)2D3 in order to individually optimize the dosage of vitamin D 
supplementation. Our data also suggest that activity of 24-hydroxylase increases 
after vitamin D supplementation.
Keywords: Vitamin D metabolites; Vitamin D supplementation; Vitamin D 
Metabolite Ratio; Randomized controlled trial; 24,25-dihydroxy vitamin D
111
introDuction
Vitamin D plays an essential role in calcium and phosphate homeostasis [1]. Vitamin 
D status is most commonly assessed by determining the 25-hydroxyvitamin D 
(25(OH)D) concentration in serum or plasma. However, several other vitamin 
D-related metabolites can be measured to provide a better understanding of 
individual vitamin D status and metabolism. Among them, 24,25(OH)2D has
emerged as a metabolite with potentially high utility [2]
In the kidneys, 25(OH)D is converted by 1-alpha-hydroxylase (CYP27B1) into 
1,25-dihydroxyvitamin D (1,25(OH)2D; also called active vitamin D or calcitriol) 
(Figure 1). 1,25(OH)2D can bind to the vitamin D receptor (VDR) with high affinity. 
The subsequent signaling results in an increase in serum calcium and phosphate 
concentrations, mainly mediated by an increased intestinal uptake. In addition, 
1,25(OH)2D has effects on the parathyroid gland, kidneys and bones, all resulting 
in an increase in serum calcium and phosphate concentrations [1]. Furthermore, 
1,25(OH)2D has major effects on modulating the immune system, which might 
be relevant for the treatment of autoimmune diseases, infections, cancer and 
cardiovascular diseases [3]. An excess of both 1,25(OH)2D and/or 25(OH)D lead 
to their catabolism by the enzyme 24-hydroxylase (CYP24A1). This results in the 
formation of metabolites 1,24,25(OH)2D and 24,25(OH)2D, respectively [4]. 
It is still unclear whether 24,25(OH)2D has a physiological role in humans [5
Figure 1. Metabolism of vitamin 
D. Vitamin D3 (cholecalciferol) is 
produced in the skin when exposed 
to sunlight. The hepatic enzyme 
CYP2R1 then converts this into 
25(OH)D3 (calcifediol). In the kidney 
25(OH)D3 can be converted into the 
active form, 1,25(OH)2D3 (calcitriol), 
by CYP27B1 (1-α-hydroxylase). In the 
kidney, CYP24A1 (24-hydroxylase) 




Using an LC-MS/MS method, 25(OH)D and 24,25(OH)2D can be measured 
simultaneously, which allows for determination of the 24,25(OH)2D/25(OH)D ratio, 
also known as the vitamin D metabolite ratio (VMR) [2] The VMR is an indicator 
of CYP24A1 activity and thereby of vitamin D catabolism. It is currently used for 
diagnosing idiopathic infantile hypercalcaemia, a rare genetic disorder in which a 
mutation in CYP24A1 results in severe hypercalcemia and suppressed parathyroid 
hoemone (PTH) levels [5]. The VMR may also reflect vitamin D receptor (VDR) 
activity since CYP24A1 expression is upregulated in response to 1,25(OH)2D [2] 
In recent years, there has been an increasing interest in the use of the VMR 
when assessing vitamin D status. For example, it has been postulated to better 
reflect vitamin D deficiency [6] In addition, it has been speculated that the ratio 
could provide useful information on bone health [7]. Interestingly, several studies 
show that the VMR can predict the change seen in 25(OH)D after vitamin D 
supplementation, although results are inconclusive [6,8–11]. The CYP24A1 activity 
could be partially responsible for the individual differences seen in the effect of 
vitamin D supplementation on serum levels of 25(OH)D. Theoretically, if CYP24A1 
activity indeed is a major predictor of the effect of vitamin D supplementation, 
the VMR could be used to personalize the treatment dosage. At present, 25(OH)
D concentrations at start of supplementation as well as BMI, age, ethnicity and 
genetic background have been most commonly studied in regard to predicting 
the response to vitamin D supplementation, and studies involving 1,25(OH)2D, 
24,25(OH)2D, free and bioavailable 25(OH)D and the VMR are scarce [12]
Therefore, we set out to determine whether baseline VMR measurements 
can predict changes in vitamin D-related metabolite levels after vitamin 
D supplementation. To that extent, we measured 25(OH)D3, 1,25(OH)2D 
and 24,25(OH)2D3 in a randomized clinical trial of patients (25(OH)D < 75 
nmol/L) receiving vitamin D supplementation [13]. We hypothesized that 
measurements of baseline VMR would be advantageous over baseline 25(OH)D 
measurements in the prediction of the change in 25(OH)D upon supplementation.
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materials anD methoDs 
Study cohort
The present post-hoc analysis was conducted in adults (>18 years old) with 25(OH)
D levels <75 nmol/L and hypertension, who completed the randomized placebo 
controlled Styrian Vitamin D Hypertension Trial (NCT02136771). The participants 
of this trial were treated with either placebo or 2800IE daily of vitamin D3 (Oleovit 
D3, Fresenius Kabi Austria) for 8 weeks. 188 study participants completed the original 
study and sufficient material for analysis from both study visits was available for 106 
of these subjects. The details regarding the study, including inclusion and exclusion 
criteria, can be found in the publication of the original study by Pilz et al. [13].
Study participants provided written informed consent. The study complies 
with the Declaration of Helsinki and was approved by the ethics committee of the 
Medical University of Graz, Austria.
Measurements
For the original study by Pilz et al, the 25(OH)D levels were determined with the
ChemiLuminescence assay (IDS-iSYS 25-hydroxyvitamin D assay; Immunodiagnostic 
Systems Ltd.,Boldon, UK) on an IDS-iSYS multidiscipline automated analyser [13]. 
The intra- and inter-assay CVs were 6.2% and 11.6%, respectively.
In the present study, 25(OH)D3 and 24,25(OH)2D3 were measured in plasma 
samples by isotope dilution liquid chromatography-tandem mass spectrometry at 
the Endocrine Laboratory of the Amsterdam UMC, as described previously [14]. For 
25(OH)D3, the lower limit of quantitation (LLOQ) was 1.2 nmol/L and the inter- 
and intra-assay coefficients of variation (CV) were 6% and 3%, respectively. For 
24,25(OH)2D3, the LLOQ was 0.1 nmol/L and the inter- and intra-assay coefficients 
of variation (CV) were 9% and 5%, respectively. 25(OH)D2 was also measured, but as 
the concentration were all very low (<7.9 nmol/L) and supplementation was given as 
25(OH)D3, these data were not taken into account in this paper. In order to calculate 
the VMR and as it is the golden standard, the LC/MS-MS method was used for the 
current study. Using this method, 7 subjects had 25(OH)D levels >75 nmol/L at 
baseline. Measurements of other study parameters have been described previously 
[13] Measurements of others study parameters have been described previously [12].
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To calculate free and biologically available 25(OH)D3 we used the equations from 
Powe et al. [15].
Statistical analysis
Continuous data following a normal distribution are reported as means with 
standard deviations (SD). Variables with a skewed distribution are shown as 
medians with interquartile ranges. Categorical variables are shown as percentages 
of observations. Groups at baseline were compared using the unpaired Students 
t-test, the Mann-Whitney U test or the chi-squared test. Skewed variables were log 
transformed before being used in parametric analyses. 
The changes from baseline for 25(OH)D3, 1,25(OH)2D and 
24,25(OH)2D3 in the vitamin D treated group were calculated as the 
difference between the value at the final study visit and the value at baseline. 
They are depicted as Δ25(OH)D3, Δ1,25(OH)2D and Δ24,25(OH)2D3. 
VMR was calculated as the ratio between 24,25(OH)2D3 and 25(OH)D3. 
Analysis of covariance (ANCOVA) was used to calculate the treatment effects 
with adjustment for baseline values. Pearson correlation analysis was used to determine 
the strength of associations between vitamin D related parameters and Δ25(OH)D3, 
Δ1,25(OH)2D as well as Δ24,25(OH)2D3. Bonferroni correction was applied to account 
for multiple testing. Univariate linear regression analysis was used to determine the 
relation between Δ25(OH)D3 and baseline 25(OH)D3, 24,25(OH)2D3 and VMR.
Using the LC/MS-MS method, 7 subjects had 25(OH)D levels >75 nmol/L at 
baseline. Therefore, we explored whether inclusion of these subjects had an effect 
on the analyses. In addition, we also investigated whether the inclusion of only 
subjects with 25(OH)D levels <50 nmol/L at baseline would affect the analyses.
If outliers were detected in the analyses by the software defined as cases with 
standardized residuals greater than 3 standard deviations for ANCOVA analyses 
or as cases with values higher or lower than 1.5*IQR (interquartile range) for 
correlation analyses, they were removed and the analysis repeated to determine 
their potential effect on the analysis. In the case of Pearson correlation analyses, 
one extreme outlier was removed (25(OH)D > 4xSD at baseline) because of 
its significant effect on all of the analyses. This is marked in the results section. 
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If the outliers had no significant effect on the analysis, the results including the 
outliers are reported. A p-value < 0.05 was considered statistically significant. 
All analyses were performed using S.P.SS version 25 (S.P.SS, Chicago, IL, USA).
results
The baseline characteristics of study participants can be found in Table 1. There 
were no differences between the placebo and vitamin D treated groups in any of the 
parameters at baseline. 
The calculated treatment effects after vitamin D supplementation are 
depicted in Table 2. We observed significant treatment effects for all included
Table 1. Baseline characteristics.
Parameter All ( n = 106) Placebo (n = 54) Vitamin D (n = 52) p-value
Age (years) 62.0 (51.3 - 68.7) 64.8 (50.8 - 70.2) 59.6 (52.4 - 66.6) 0.318
Body mass index (kg/m2) 30.0 ± 5.4 29.7 ± 5.9 30.3 ± 4.9 0.562
Gender (% female) 57 57 56 0.865
24,25(OH)2D3 (nmol/L) 3.5 ± 1.6 3.4 ± 1.5 3.6 ± 1.5 0.419
25(OH)D3 (nmol/L) 48 ± 18 46 ± 19 49 ± 18 0.401
VMR ((nmol/L/
(nmol/L))
0.073 ± 0.017 0.072 ± 0.018 0.073 ± 0.017 0.768
PTH (pmol/L) 5.5 (4.1 - 6.7) 5.5 (4.0 - 6.7) 5.3 (4.1 - 6.7) 0.779
1,25(OH)2D3 (pmol/L) 126 ± 53 118 ± 52 133 ± 52 0.142
Serum phosphate 
(nmol/L)c
0.94 ± 0.17 0.96 ± 0.17 0.92 ± 0.16 0.282
Serum calcium (mmol/L) 2.26 (2.21 - 2.33) 2.26 (2.21 - 2.34) 2.26 (2.20 - 2.33) 0.773
eGFR (mL/min/1.73m2) 72 ± 17 69 ± 16 74 ± 18 0.152
24h urinary calcium 
excretion (mmol/24h)
3.30 (1.90 - 5.00) 2.95 (1.83 - 4.78) 3.70 (2.10 - 6.30) 0.222
Calculated free 25(OH)
D3 (pmol/L)
15 (9 - 21) 12 (8 - 21) 17 (11 - 20) 0.153
Vitamin D binding 
protein (μg/mL)
247.1 ± 109.5 254.8 ± 110.6 239.3 ± 109.0 0.772
Calculated bioavailable 
25(OH)D3 (nmol/L)
5.9 (3.9 - 8.2) 5.2 (3.2 - 8.5) 6.6 (4.1 - 8.0) 0.149
1,25(OH)2D3/ 25(OH)D3 
((nmol/L)/(nmol/L))
0.0023 (0.0019 - 
0.0036)
0.0027 (0.0018 - 
0.0039)






0.036 (0.025 - 
0.05)
0.036 (0.024 - 
0.051)





vitamin D related parameters. For 25(OH)D3, the treatment effect was 32 nmol/L 
(95% CI: 26 to 39; p < 0.001), for 1,25(OH)2D 26 pmol/L (9 to 42; p = 0.003), for 
24,25(OH)2D3 3.3 nmol/L (2.7 to 3.9; p < 0.001), for VMR 0.015 (nmol/L)/(nmol/L) 
(0.010-0.019; p < 0.001), for calculated free 25(OH)D3 12 pmol/L (6 to 18; p < 
0.001), for calculated bioavailable 25(OH)D3 4.66 nmol/L (2.63-6.68; p < 0.001), 
for the 1,25(OH)2D/25(OH)D3 ratio -0.0010 (nmol/L)/(nmol/L) (-0.0013 to 
-0.0006; p < 0.001) and for the 1,25(OH)2D/24,25(OH)2D3 ratio -0.020 (nmol/L)/
(nmol/L) (-0.026 to -0.015; p < 0.001). In the subgroup of subjects with 25(OH)D3 
levels below 50 nmol/L, the treatment effects and p-values were comparable for all 
parameters.
The overall correlation between 25(OH)D3 and 24,25(OH)2D3 at baseline was r 
= 0.815, p < 0.001. Results of the regression analyses of the Δ25(OH)D3 in the vitamin 
D supplemented group are shown in Figure 2. The slope of the linear regression, 
p-values and R2 value are highly similar for baseline 25(OH)D3 and 24,25(OH)2D3.
The VMR, however, could not predict the increase in 25(OH)D3 concentration. The 
results of the correlation analyses in the vitamin-D-treated group are summarized 
in Table 3. None of the vitamin-D-related parameters correlated significantly with 
∆25(OH)D3 or ∆1,25(OH)2D after Bonferroni correction. Also, in the subgroup of 
subjects with 25(OH)D levels below 50 nmol/L, none of the parameters correlated 
significantly with ∆25(OH)D3 or ∆1,25(OH)2D after Bonferroni correction. For 
∆25(OH)D3, a trend was seen for baseline 25(OH)D3 and baseline 24,25(OH)2D3 
(r = −0.388, p = 0.056 and r = −0.374, p = 0.056). This trend with ∆25(OH)D3 
was also observed for calculated free 25(OH)D3 and calculated bioavailable 
25(OH)D3 (r = −0.373, p = 0.056 and r = −0.375, p = 0.056). ∆24,25(OH)2D3 was 
significantly associated with baseline 25(OH)D3, 24,25(OH)2D3, calculated free 
25(OH)D3 and calculated bioavailable 25(OH)D3 (r = −0.562, p < 0.001; r = −0.476, 
p = 0.003; r = −0.382, p = 0.048 and r = −0.393, p = 0.032, respectively), but not 
with other parameters. In the subgroup of subjects with 25(OH)D3 levels below 50 




Figure 2.Univariate linear regression analysis for the change in 25(OH)D3 concentration in 
the vitamin D intervention group and (a) baseline 25(OH)D3, (b) baseline 24,25(OH)2D3 
and (c) baseline VMR (Vitamin D Metabolite Ratio).
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Table 2. ANCOVA analysis for the effect of vitamin D or placebo treatment on vitamin D 
related parameters. 






Placebo, N=54 46 ± 19 45 ± 20
32 (26 to 39) < 0.001
Vitamin D, N=52 49 ± 18 79 ± 19
1,25(OH)2D 
(pmol/L)
Placebo, N=52 118 ± 52 114 ± 39
26 (9 to 42) 0.003
Vitamin D, N=52 133 ± 52 150 ± 63
24,25(OH)2D3 
(nmol/L)
Placebo, N=54 3.4 ± 1.5 3.3 ± 1.8
3.3 (2.7 to 3.9) < 0.001
Vitamin D, N=52 3.6 ± 1.6 6.8 ± 1.7
VMR
Placebo, N=54 0.072 ± 0.018 0.071 ± 0.017 0.015 (0.010 




Placebo, N=53 12 (8 - 21) 12 (8 - 18)





Placebo, N=53 5.22 (3.15 - 
8.51)
4.99 (2.95 - 
6.83) 4.66 (2.63 to 
6.68) < 0.001Vitamin D, N=51 6.60 (4.10 - 
8.02)




Placebo, N=52 0.0027 (0.0018 
- 0.0039)
0.0026 (0.0019 










Placebo, N=52 0.036 (0.024 - 
0.051)
0.037 (0.026 - 
0.052) -0.020 (-0.026 
to -0.015) < 0.001Vitamin D, N=52 0.035 (0.026 - 
0.050)
0.022 (0.016 - 
0.028)
* Log transformed parameters
Correlation analyses after adjustment for gender, age, BMI, PTH, eGFR, serum 
phosphate and serum calcium showed that none of the vitamin D-related parameters 
were significantly associated with Δ25(OH)D3 or Δ1,25(OH)2D after Bonferroni 
correction (Supplemental table 1). However, when corrected for the above 
mentioned parameters, only baseline 25(OH)D3 was still significantly associated 
with Δ24,25(OH)2D3 (r = -0.657, p = 0.008). In the subgroup of subjects with 
25(OH)D3 levelsbelow 50 nmol/L, none of the parameters correlated significantly 
with ∆25(OH)D3, ∆1,25(OH)2D or ∆24,25(OH)2D3 after Bonferroni correction.
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Table 3. Pearson correlations with unadjusted p-values and Bonferroni adjusted p-values 
of baseline vitamin D related parameters with the changes from baseline of 25(OH)D3, 
1,25(OH)2D and 24,25(OH)2D3 after vitamin D supplementation.
Baseline parameters Δ25(OH)D3 Δ1,25(OH)2D Δ24,25(OH)2D3
25(OH)D3
r -0.388 -0.142 -0.562
p-value 0.005 0.322 < 0.001
Adjusted p-value 0.056 1.000 < 0.001
1,25(OH)2D
r -0.287 -0.260 -0.272
p-value 0.041 0.065 0.053
Adjusted p-value 0.328 0.520 0.424
24,25(OH)2D3
r -0.374 -0.122 -0.476
p-value 0.007 0.392 < 0.001
Adjusted p-value 0.056 1.000 0.003
VMR
r -0.109 -0.027 -0.015
p-value 0.448 0.850 0.916
Adjusted p-value 1.000 1.000 1.000
Calculated free 
25(OH)D3*
r -0.373 -0.281 -0.382
p-value 0.007 0.046 0.006




r -0.375 -0.280 -0.393
p-value 0.007 0.047 0.004
Adjusted p-value 0.056 0.376 0.032
1,25(OH)2D
/25(OH)D3*
r -0.004 -0.058 0.176
p-value 0.980 0.687 0.216
Adjusted p-value 1.000 1.000 1.000
1,25(OH)2D 
/24,25(OH)2D3*
r 0.053 -0.028 0.181
p-value 0.711 0.843 0.204
Adjusted p-value 1.000 1.000 1.000
*Log transformed parameters
Discussion
The goal of our study was to assess whether vitamin D metabolites can predict 
the increase of 25(OH)D after vitamin D supplementation. As elaborated above, 
CYP24A1 activity (24-hydroxylase) is reflected by the ratio of 24,25(OH)2D 
over 25(OH)D, i.e. the VMR. In addition, the ratio between 1,25(OH)2D and 
24,25(OH)2D3 was recently proposed as part of a three-dimensional model for 
assessing vitamin D metabolic pathways [16] It was previously suggested that 
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vitamin D metabolites and their ratios could provide additional information for 
predicting vitamin D treatment response [8,9]. The findings in this vitamin D RC.T., 
in patients with 25(OH)D levels <75 nmol/L and hypertension do not support this 
hypothesis. 
In our study, the VMR did not predict Δ25(OH)D3 in the treatment arm of the 
RC.T. In a regression model, baseline 24,25(OH)2D3 and baseline 25(OH)D3 did, 
with comparable strength and magnitude, predict the increase in 25(OH)D3 upon 
treatment. When adjusting for multiple testing in correlation analyses, no correlations 
of any of the included parameters with Δ25(OH)D3 were significant anymore. Yet, 
we did observe trends for Δ25(OH)D3 with baseline 25(OH)D3, 24,25(OH)2D3, 
free 25(OH)D3 and bioavailable 25(OH)D3. Notwithstanding their borderline 
significance, the strength of the correlations is highly similar between these parameters 
and they do not seem to be superior to baseline 25(OH)D. According to these data, 
we can infer that CYP24A1 activity, measured by the VMR, does not predict the 
individual differences in the increase in 25(OH)D after vitamin D supplementation.
Concerning the VMR, the results of this study are in accordance with 
several other published reports. Saleh et al. performed an RC.T. of 4 weeks with 
107 participants receiving a single 100,000 IU dose of vitamin D or placebo [11]. 
The VMR could not predict the increase of 25(OH)D after 4 weeks, whereas 
25(OH)D did predict this increase with a similar R2-value to our data. However, 
their data indicated that 24,25(OH)2D3 could not predict the Δ25(OH)D3, 
whereas in our study it did. Aloia et al. reported on the predictive properties of 
VMR in four different small samples (between 14 and 16 participants per group) 
of placebo or 800, 2000 or 4000 IU vitamin D daily for 10 weeks [6] They did 
not show an advantage of the VMR as predictor, compared to baseline 25(OH)D, 
24,25(OH)2D3 or free 25(OH)D. Binkley et al. investigated the effect of 1800IU 
of vitamin D in 62 postmenopausal women after four months and measured 
vitamin D metabolites [10]. They observed that neither VMR, 25(OH)D, 
24,25(OH)2D3 nor free 25(OH)D was related to the observed increase in 25(OH)D.
On the contrary, other published studies did suggest a predictive role for the 
VMR. The study by Wagner et al. included young adults with a mean age of around 
27 years that received 28,000 IU (equivalent to 4000 IU per day) of vitamin D once 
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per week for 8 weeks in the form of a supplement or fortified cheese. Wagner et al. 
showed that the VMR predicted the increase in vitamin-D-receiving subjects (R2 = 
−0.38, p = 0.004, n = 60) [8]. Also, Cashman et al. reported a significant correlation 
between the VMR and the change after vitamin D supplementation (R2 = 0.15, p < 
0.01) in a study including subjects above 50 years of age that were treated for 15 weeks 
by 20 µg vitamin D (800 IU) per day [9]. Of note, both studies did not report the R2 
-value of baseline 25(OH)D with its increase after supplementation. Therefore, it is 
not possible to conclude whether the VMR was superior to 25(OH)D in this aspect.
Changes in other vitamin D related parameters after vitamin D 
treatment were also studied. To that end, we assessed if Δ1,25(OH)2D and 
Δ24,25(OH)2D3 could be predicted by baseline parameters included in the 
study. We found no correlation between any tested baseline parameter and 
Δ1,25(OH)2D. 1,25(OH)2D levels are mainly regulated by calcium levels, which 
could explain this observation [12] On the other hand, baseline 25(OH)D3, 
24,25(OH)2D3, calculated free 25(OH)D3 and calculated bioavailable 25(OH)D3 
all showed a significant correlation with Δ24,25(OH)2D3 . The clinical relevance 
of this observation is, in our opinion, unclear and should be further studied.
In our study, we observed an increase in VMR upon vitamin D treatment. 
This suggests an increase in CYP24A1 activity and catabolism of 25(OH)D upon 
supplementation. A concurrent decrease in the 1,25(OH)2D/25(OH)D3 ratio implies a 
reduced conversion of 25(OH)D to 1,25(OH)2D. Indeed, this suggests the physiological 
shift from anabolic to catabolic pathways when an excess of vitamin D exists. This 
is also supported by the significant decrease in the 1,25(OH)2D/24,25(OH)2D3 
ratio. In the present study, and all aforementioned studies, the correlation 
coefficients between baseline 25(OH)D and Δ25(OH)D3 after supplementation 
were negative, which implies that the change in 25(OH)D3 after vitamin D 
treatment is smaller in individuals with higher baseline 25(OH)D3 levels [8–10].
We acknowledge that this study has several limitations. First, the results 
are derived from post hoc analyses. Second, the study population consisted of 
hypertensive subjects with 25(OH)D levels <75 nmol/L; therefore, the findings 
might not be readily extrapolated to the general population. Furthermore, for 
the inclusion criterion of vitamin D insufficiency, the 25(OH)D concentrations 
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were measured at study baseline using a chemiluminescence assay, while mass 
spectrometry-based methods are currently the gold standard [2] However, for the 
current study 25(OH)D and 24,25(OH)2D were re-measured using a dedicated LC-
MS/MS method. In addition, the intervention period of 8 weeks was relatively short 
and only a small number of subjects were severely vitamin D deficient. Vitamin D 
insufficiency was defined as a 25(OH)D of <75 nmol/L in the original study by Pilz 
et al. [13]. There is still an ongoing debate as to whether the cut-off levels should 
be set at <50 nmol/L or <75 nmol/L [17,18]. In addition, vitamin D sufficiency 
was defined by measurements of baseline 25(OH)D3, which is currently the critical 
measurement for defining vitamin D status [19]. Some studies suggest that free 
25(OH)D3 could be a better marker for assessing vitamin D status [20]. In our 
study, calculated free 25(OH)D3 did not predict ∆25(OH)D3 after supplementation 
better than baseline 25(OH)D3. The RC.T. design and the successful vitamin D 
intervention are strengths of this study. Also, a high number of parameters were 
measured with gold-standard methods. In contrast to the majority of exploratory 
studies on the VMR, p-values of the correlations were adjusted for multiple testing.
In summary, we show that 25(OH)D3, 24,25(OH)2D3 and the VMR 
increase after vitamin D treatment. However, 24,25(OH)2D3 and the VMR 
could not predict 25(OH)D3 levels after vitamin D treatment in this cohort 
better than baseline 25(OH)D3. As this has been corroborated by other studies, 
it implicates the routine measurement of 24,25(OH)2D3 will probably be 
of no added value when personalizing the treatment dosage of vitamin D.
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supplemental Data
Table S1. Pearson correlations of baseline vitamin D related parameters adjusted for gender, 
age, BMI, PTH, eGFR, serum phosphate and serum calcium, with the changes from baseline 
of 25(OH)D, 1,25(OH)2D and 24,25(OH)2D after vitamin D supplementation. P-values 





r -0.508 -0.277 -0.657
p-value 0.013 0.201 0.001
Adjusted p-value 0.104 1.000 0.008
1,25(OH)2D
r -0.350 -0.171 -0.430
p-value 0.102 0.435 0.040
Adjusted p-value 0.816 1.000 0.320
24,25(OH)2D3
r -0.490 -0.129 -0.597
p-value 0.018 0.559 0.003
Adjusted p-value 0.440 1.000 0.096
VMR
r -0.064 0.137 -0.516
p-value 0.773 0.534 0.012
Adjusted p-value 1.000 1.000 0.096
Calculated free 
25(OH)D3*
r -0.451 -0.363 -0.399
p-value 0.031 0.089 0.059




r -0.451 -0.363 -0.404
p-value 0.031 0.089 0.056
Adjusted p-value 0.248 0.712 0.448
1,25(OH)2D
/25(OH)D3*
r 0.122 0.272 0.218
p-value 0.578 0.209 0.318
Adjusted p-value 1.000 1.000 1.000
1,25(OH)2D 
/24,25(OH)2D3*
r 0.126 0.136 0.211
p-value 0.565 0.536 0.333
Adjusted p-value 1.000 1.000 1.000

